TY  - JOUR
A1  - Weiler, Nina
A1  - Zeuzem, Stefan
A1  - Welker, Martin-Walter
T1  - Concise review : interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection
T2  - World journal of gastroenterology
N2  - Chronic hepatitis C is a major reason for development of cirrhosis and hepatocellular carcinoma and a leading cause for liver transplantation. The development of direct-acting antiviral agents lead to (pegylated) interferon-alfa free antiviral therapy regimens with a remarkable increase in sustained virologic response (SVR) rates and opened therapeutic options for patients with advanced cirrhosis and liver graft recipients. This concise review gives an overview about most current prospective trials and cohort analyses for treatment of patients with liver cirrhosis and liver graft recipients. In patients with compensated cirrhosis Child-Pugh-Turcotte (CTP) class A, all approved agents are safe and SVR rates do not significantly differ from patients without cirrhosis in general. In patients with decompensated cirrhosis CTP class B or C, daclastasvir, ledipasvir, velpatasvir, and sofosbuvir are approved, and SVR rates higher than 90% can be achieved. Especially for patients with a model of end stage liver disease score higher than 15 and therefore eligible for liver transplantation, data is scarce. Reported SVR rates in patients with cirrhosis CTP class C are lower compared to patients with a less severe liver disease. In liver transplant recipients with a maximum of CTP class A, SVR rates are comparable to patients without LT. Patients with decompensated graft cirrhosis should be treated on an individual basis.
KW  - hepatitis C
KW  - cirrhosis
KW  - liver transplantation
KW  - direct antiviral agents
KW  - interferon-free antiviral treatment
Y1  - 2017
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/42603
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-426031
SN  - 2219-2840
SN  - 1007-9327
N1  - Copyright © The author(s) 1995-2017. Published by Baishideng Publishing Group Inc. All rights reserved. Articles published by this open-access journal are distributed under the terms of the Creative Commons Attribution-Noncommercial (CC BY-NC 4.0) License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.
VL  - 22
IS  - 41
SP  - 9044
EP  - 9056
PB  - WJG Press
CY  - Beijing
ER  -